Composition of Certain Financial Statement Captions (Tables)

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Composition of Certain Financial Statement Captions

	For the years ended December 31,
(In thousands)	2022		2021
Accounts receivable, net
Accounts receivable	$	131,474	$	261,476
Less: allowance for doubtful accounts	(4,162)		(1,839)
	$	127,312	$	259,637
Inventories, net
Finished products	$	37,139	$	44,107
Consumable supplies	31,275		39,447
Work in-process	2,449		1,615
Raw materials	6,771		6,112
Less: inventory reserve	(3,574)		(4,779)
	$	74,060	$	86,502
Other current assets and prepaid expenses
Prepaid supplies	$	7,918	$	10,641
Prepaid insurance	4,496		4,383
Taxes recoverable	8,191		5,598
Other receivables	13,105		353
Other	6,252		6,195
	$	39,962	$	27,170
Property, plant and equipment, net:
Machinery, medical and other equipment	$	136,048	$	127,633
Leasehold improvements	25,516		27,478
Furniture and fixtures	11,271		11,638
Automobiles and aircraft	12,808		12,602
Software	14,218		14,507
Building	18,314		10,661
Land	2,317		2,421
Construction in process	4,793		6,113
Less: accumulated depreciation	(142,406)		(133,326)
	$	82,879	$	79,727
Intangible assets, net:
Technologies	$	826,282	$	246,101
Customer relationships	314,854		314,823
Trade names	49,752		49,770
Covenants not to compete	12,911		12,920
Licenses	5,988		5,766
Product registrations	6,831		6,995
Other	5,861		6,128
Less: accumulated amortization	(398,959)		(320,820)
	$	823,520	$	321,683

	For the years ended December 31,
(In thousands)	2022		2021
Accrued expenses:
Employee benefits	$	33,765	$	45,939
Inventory received but not invoiced	7,830		40,446
Commitments and contingencies	4,295		27,819
Clinical trials	4,700		4,867
Finance leases short-term	2,809		2,257
Professional fees	1,820		2,121
Contingent consideration	62		487
Contract liabilities	—		258
Other	42,988		69,299
	$	98,269	$	193,493
Other long-term liabilities:
Mortgages and other debts payable	$	9,098	$	2,224
Finance leases long-term	7,089		2,924
Contingent consideration	974		2,350
Contract liabilities	138		208
Other	10,072		7,356
	$	27,371	$	15,062

Summary of Valuation Allowance

The following table reflects the changes in the allowance for doubtful accounts, provision for inventory reserve and tax valuation allowance accounts:

(In thousands)	Beginning balance		Charged to expense	Written-off	Charged to other	Ending balance
2022
Allowance for doubtful accounts	$	(1,839)	(304)	(2,019)	—	$	(4,162)
Inventory reserve	$	(4,779)	(4,059)	5,264	—	$	(3,574)
Tax valuation allowance	$	(260,397)	(24,579)	—	5,764	$	(279,212)
2021
Allowance for doubtful accounts	$	(2,055)	(369)	585	—	$	(1,839)
Inventory reserve	$	(2,321)	(6,461)	4,003	—	$	(4,779)
Tax valuation allowance	$	(303,326)	34,496	—	8,433	$	(260,397)

Changes in Goodwill

The following table summarizes the changes in Goodwill by reporting unit during the years ended December 31, 2022 and 2021.

	2022										2021
(In thousands)	Gross goodwill at January 1		Cumulative impairment at January 1		Acquisition and dispositions		Foreign exchange and other		Balance at December 31st		Gross goodwill at January 1		Cumulative impairment at January 1		Foreign exchange and other		Balance at December 31st
Pharmaceuticals
CURNA	$	4,827	$	(4,827)	$	—	$	—	$	—	$	4,827	$	(4,827)	$	—	$	—
Rayaldee	86,554		—		—		(4,768)		81,786		93,418		—		(6,865)		86,554
FineTech	11,698		(11,698)		—		—		—		11,698		(11,698)		—		—
ModeX	—				80,432		—		80,432		—		—		—		—
OPKO Biologics	139,784		—		—		—		139,784		139,784		—		—		139,784
OPKO Chile	3,760		—		—		7		3,767		4,505		—		(745)		3,760
OPKO Health Europe	7,478		—		—		(421)		7,057		8,086		—		(608)		7,478
OPKO Mexico	100		(100)		—		—		—		100		(100)		—		—
Transition Therapeutics	3,421		(3,421)		—		—		—		3,421		(3,421)		—		—
Diagnostics
BioReference	434,809		—		(151,784)		—		283,025		434,809		—		(151,784)		283,025
OPKO Diagnostics	17,977		(17,977)		—		—		—		17,977		(17,977)		—		—
	$	710,408	$	(38,023)	$	(71,352)	$	(5,182)	$	595,851	$	718,625	$	(38,023)	$	(160,002)	$	520,601